A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model

Trial Profile

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

At a glance

  • Drugs RV 521 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors ReViral
  • Most Recent Events

    • 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
    • 05 Feb 2018 Results published in a ReViral media release.
    • 05 Feb 2018 Primary endpoint (Change in viral load) has been met, according to results published in a ReViral media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top